Full Text View
Tabular View
No Study Results Posted
Related Studies
Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis
This study has been completed.
Study NCT01423110   Information provided by Novartis

First Received on August 12, 2011.   Last Updated on August 16, 2012   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Sporadic Inclusion Body Myositis
Additional conditions recognized in this trial
Myositis
Myositis, Inclusion Body
More general conditions related to this trial
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neuromuscular Diseases
Interventions listed in this trial
BYM338
Placebo
Sponsors listed in this trial
Novartis Pharmaceuticals


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services